Diabetes Drug Linked to Lower Risk of Heart Disease
Using
liraglutide, an injectable drug widely used to lower blood sugar
levels, may help reduce risk of myocardial infarction, stroke or
cardiovascular death, suggests a study.
Liraglutide is a diabetes medication in clinical use since 2009. It is a glucagon-like peptide 1 receptor agonist that lowers blood sugar and reduces body weight.
The findings, showed that people who used liraglutide had five fewer major cardiovascular events for three years.
Liraglutide is a diabetes medication in clinical use since 2009. It is a glucagon-like peptide 1 receptor agonist that lowers blood sugar and reduces body weight.
The findings, showed that people who used liraglutide had five fewer major cardiovascular events for three years.
According to a senior researcher,
Our study provides support for the cardiovascular effectiveness of liraglutide among a broader unselected group of patients, providing important confirmatory evidence from routine clinical practice. We believe it may be of interest to drug regulators, clinical guidelines, physicians and patients.
Use of liraglutide was also associated with reduced risk of cardiovascular death and any cause of death.
The Study
For
the study, the team used several nationwide registers with information
on prescription drugs, diseases and other data from more than 46,000
patients in Sweden and Denmark between 2010 and 2016.
Around 23,000 patients initiating treatment with liraglutide were compared with the same number of patients initiating treatment with another diabetes drug, DPP4 inhibitors.
The main outcome in the study was on major cardiovascular events, defined as myocardial infarction, stroke or cardiovascular death.
The rate of major cardiovascular events was 14 per 1,000 person-years among patients using liraglutide and 15.4 per 1,000 among patients using DPP4 inhibitors, a statistically significant difference, the researchers said.
Around 23,000 patients initiating treatment with liraglutide were compared with the same number of patients initiating treatment with another diabetes drug, DPP4 inhibitors.
The main outcome in the study was on major cardiovascular events, defined as myocardial infarction, stroke or cardiovascular death.
The rate of major cardiovascular events was 14 per 1,000 person-years among patients using liraglutide and 15.4 per 1,000 among patients using DPP4 inhibitors, a statistically significant difference, the researchers said.
THIS IS ONLY FOR INFORMATION, ALWAYS CONSULT YOU PHYSICIAN BEFORE HAVING ANY PARTICULAR FOOD/ MEDICATION/EXERCISE/OTHER REMEDIES. PS- THOSE INTERESTED IN RECIPES ARE FREE TO VIEW MY BLOG- https://gseasyrecipes.blogspot.com/ FOR INFO ABOUT KNEE REPLACEMENT, YOU CAN VIEW MY BLOG- https:// kneereplacement-stickclub.blogspot.com/ FOR CROCHET DESIGNS https://gscrochetdesigns.blogspot.com
Labels: diabetes drug, DPP4 inhibitors, glucagon-like peptide-1 (GLP1), heart diseases, liraglutide, lowers blood sugar, lowers risk, myocardial infarction, reduces, stroke, Weight
0 Comments:
Post a Comment
<< Home